STOCK TITAN
  1. Home
  2. Sec-filings
  3. IRD
  4. [ARS] Opus Genetics, Inc. SEC Filing

[ARS] Opus Genetics, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
ARS
ARS - Opus Genetics, Inc.

ARS Filing - Opus Genetics, Inc.

This filing is available as a PDF document.

Filing Type: ARS

Company: Opus Genetics, Inc. (IRD)

Acceptance Date: 2026-03-23T16:08:02.000Z

View PDF Document

Source: View Original Filing on SEC EDGAR

Opus Genetics

NASDAQ:IRD

View IRD Stock Overview →

IRD Rankings

#3939 Ranked by Market Cap
N/A Ranked by Dividends

IRD Latest News

Mar 24, 2026
Opus Genetics Named to Fast Company’s Annual List of the World’s Most Innovative Companies of 2026
Mar 10, 2026
Opus Genetics Announces Financial Results for Full Year 2025 and Provides Corporate Update
Mar 3, 2026
Opus Genetics to Present at Upcoming Investor Conferences in March 2026
Feb 27, 2026
Opus Genetics Announces Initial Clinical Data from Phase 1/2 OPGx-BEST1 Gene Therapy Study at the Macula Society Annual Meeting
Feb 25, 2026
Opus Genetics Announces FDA Acceptance of Supplemental New Drug Application for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia

IRD Latest SEC Filings

Mar 23, 2026
[DEF 14A] Opus Genetics, Inc. Definitive Proxy Statement
Mar 18, 2026
[Form 4] Opus Genetics, Inc. Insider Trading Activity
Mar 18, 2026
[Form 4] Opus Genetics, Inc. Insider Trading Activity
Mar 18, 2026
[Form 4] Opus Genetics, Inc. Insider Trading Activity
Mar 18, 2026
[Form 4] Opus Genetics, Inc. Insider Trading Activity

IRD Stock Data

321.59M
54.65M
Biotechnology
Pharmaceutical Preparations
Link
United States
DURHAM